(19)
(11) EP 3 443 119 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
06.04.2022 Bulletin 2022/14

(45) Mention of the grant of the patent:
23.02.2022 Bulletin 2022/08

(21) Application number: 17733137.8

(22) Date of filing: 17.04.2017
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
C12Q 1/6858(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 2600/156; C12Q 1/6858; C12Q 1/6886
 
C-Sets:
C12Q 1/6858;
(86) International application number:
PCT/US2017/028013
(87) International publication number:
WO 2017/181202 (19.10.2017 Gazette 2017/42)

(54)

METHODS FOR LUNG CANCER DETECTION

VERFAHREN ZUR ERKENNUNG VON LUNGENKREBS

PROCÉDÉS DE DÉTECTION DU CANCER DU POUMON


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 15.04.2016 US 201662323589 P

(43) Date of publication of application:
20.02.2019 Bulletin 2019/08

(73) Proprietors:
  • Natera, Inc.
    San Carlos, CA 94070 (US)
  • UCL Business Ltd
    London WC1E 6BT (GB)

(72) Inventors:
  • ZIMMERMANN, Bernhard
    San Carlos, California 94070 (US)
  • CONSTANTIN, Tudor Pompiliu
    San Carlos, California 94070 (US)
  • SALARI, Raheleh
    San Carlos, California 94070 (US)
  • KIRKIZLAR, Huseyin Eser
    Los Angeles, California 90026 (US)
  • SWANTON, Robert Charles
    London Greater London WC1E 6BT (GB)
  • JAMAL-HANJANI, Mariam
    London Greater London WC1E 6BT (GB)
  • ABBOSH, Christopher
    London Greater London WC1E 6BT (GB)
  • WILSON, Gareth
    London Greater London NW1 1AT (GB)

(74) Representative: Gibbs, Richard 
Marks & Clerk LLP Aurora 120 Bothwell Street
Glasgow G2 7JS
Glasgow G2 7JS (GB)


(56) References cited: : 
WO-A1-2014/151117
WO-A1-2015/164432
   
  • M. JAMAL-HANJANI ET AL: "Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer", ANNALS OF ONCOLOGY., vol. 27, no. 5, 28 January 2016 (2016-01-28), pages 862-867, XP055407182, NL ISSN: 0923-7534, DOI: 10.1093/annonc/mdw037
  • A. NARAYAN ET AL: "Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing", CANCER RESEARCH, vol. 72, no. 14, 15 July 2012 (2012-07-15) , pages 3492-3498, XP055407873, US ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-11-4037
  • XU SONG ET AL: "Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients", CANCER LETTERS, NEW YORK, NY, US, vol. 370, no. 2, 12 November 2015 (2015-11-12), pages 324-331, XP029337565, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2015.11.005
  • Anonymus: "Ion AmpliSeq Cancer Hotspot Panel v2", , 2015, XP055409371, Retrieved from the Internet: URL:https://tools.thermofisher.com/content /sfs/brochures/Ion-AmpliSeq-Cancer-Hotspot -Panel-Flyer.pdf [retrieved on 2017-09-25]
  • E. C. DE BRUIN ET AL: "Spatial and temporal diversity in genomic instability processes defines lung cancer evolution", SCIENCE, vol. 346, no. 6206, 10 October 2014 (2014-10-10), pages 251-256, XP055409531, ISSN: 0036-8075, DOI: 10.1126/science.1253462
  • MARIAM JAMAL-HANJANI ET AL: "Community Page Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study", PLOS BIOLOGY, vol. 12, no. 7, July 2014 (2014-07), page e1001906, XP055295763, DOI: 10.1371/journal.pbio.1001906
  • CHRISTOPHER ABBOSH ET AL: "Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution", NATURE, vol. 545, no. 7655, 26 April 2017 (2017-04-26), pages 446-451, XP055409582, ISSN: 0028-0836, DOI: 10.1038/nature22364
  • Couraud Sébastien ET AL: "Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002", CLINICAL CANCER RESEARCH, vol. 20, no. 17, 1 September 2014 (2014-09-01), pages 4613-4624, XP55813405, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-3063
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).